Amarin reaches target enrollment in phase 3 trial of Miraxion for Huntington's disease

By Lisa Kerner

Charlotte, N.C., June 29 - Amarin Corp. plc said it has reached its target enrollment of 300 patients in the North American phase 3 clinical trial (Trend study) of Miraxion in Huntington's disease.

The six-month trial, being conducted by the Huntington Study Group (HSG) at 42 neurology centers in the United States and Canada, will compare Miraxion (1 gram twice daily) to a placebo.

Results will be measured using the Total Motor Score-4 subscale of the Unified Huntington's Disease Rating Scale.

While there is no one approved U.S. treatment to prevent the symptoms of Huntington's disease or delay its progression, earlier studies of Miraxion showed improvements in motor function in Huntington's disease patients.

"With over 540 patients, the combined U.S., Canadian and European trials form one of the largest therapeutic programs ever conducted in [Huntington's disease]," chief executive officer Rick Stewart said in a company news release.

"The support and involvement of the HSG has been instrumental to our success in meeting our enrollment target for such a large trial within nine months."

Amarin is a neuroscience company specializing in novel drugs for the treatment of central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.